InvestSMART

Antisense Therapeutics Limited (ASX: ANP) - Announcements

Current share price for ANP : $0.058 0.003 (4.92%)+

ASX company news and announcements for Antisense Therapeutics Limited (ANP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Antisense Therapeutics Limited (ANP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Antisense Therapeutics Limited (ANP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Antisense Therapeutics Limited (ANP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$52 Annual Report 31 Oct 2019 11:30AM $0.095 $0.058 fallen by 38.95%
$52 Appendix 3B 29 Oct 2019 10:51AM $0.090 $0.058 fallen by 35.56%
$52 Neuromuscular Drug Development Summit Poster Presentation 25 Oct 2019 9:20AM $0.099 $0.058 fallen by 41.41%
$52 Appendix 4C - quarterly 25 Oct 2019 8:43AM $0.099 $0.058 fallen by 41.41%
$52 Techknow Conference Presentation 22 Oct 2019 8:51AM $0.105 $0.058 fallen by 44.76%
$52 ANP to present at Neuromuscular Drug Development Summit USA 17 Oct 2019 10:01AM $0.100 $0.058 fallen by 42%
$52 Change in substantial holding 11 Oct 2019 2:45PM $0.100 $0.058 fallen by 42%
$52 Change in substantial holding from AEF 9 Oct 2019 3:29PM $0.105 $0.058 fallen by 44.76%
$52 Response to ASX Price Query 7 Oct 2019 2:47PM $0.120 $0.058 fallen by 51.67%
$52 Appendix 3B 4 Oct 2019 4:20PM $0.097 $0.058 fallen by 40.21%
$52 Positive preliminary results from ATL1102 DMD Phase II trial 18 Sep 2019 10:45AM $0.047 $0.058 risen by 23.40%
$52 Trading Halt 17 Sep 2019 9:48AM $0.047 $0.058 risen by 23.40%
$52 ATL1102 for DMD European regulatory interactions 2 Sep 2019 9:52AM $0.050 $0.058 risen by 16%
$52 Appendix 4E and Full Year Statutory Accounts 30 Aug 2019 4:21PM $0.050 $0.058 risen by 16%
$52 Acromegaly Early Access Program Status Update 26 Aug 2019 10:27AM $0.051 $0.058 risen by 13.73%
$52 Change in substantial holding 31 Jul 2019 2:06PM $0.052 $0.058 risen by 11.54%
$52 Phase II DMD clinical trial on track for dosing completion 24 Jul 2019 10:04AM $0.041 $0.058 risen by 41.46%
$52 Appendix 4C - quarterly 18 Jul 2019 9:56AM $0.042 $0.058 risen by 38.10%
$52 Conference Presentation 25 Jun 2019 9:08AM $0.047 $0.058 risen by 23.40%
$52 Updated Investor Presentation 29 May 2019 9:31AM $0.050 $0.058 risen by 16%
$52 Phase II clinical trial in DMD Fully Enrolled 24 May 2019 9:07AM $0.050 $0.058 risen by 16%
$52 Employee Share Ownership Plan (ESOP) 26 Apr 2019 8:37AM $0.044 $0.058 risen by 31.82%
$52 Appendix 4C - quarterly 26 Apr 2019 8:29AM $0.044 $0.058 risen by 31.82%
$52 Phase II clinical trial in DMD Update 4 Apr 2019 9:52AM $0.040 $0.058 risen by 45%
$52 Change in substantial holding 18 Mar 2019 11:01AM $0.039 $0.058 risen by 48.72%

276 - 300 of 707 results

Page 12 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.